title: Towards new business models for R&D for novel antibiotics.
abstract: In the face of a growing global burden of resistance to existing antibiotics, a combination of scientific and economic challenges has posed significant barriers to the development of novel antibacterials over the past few decades. Yet the bottlenecks at each stage of the pharmaceutical value chain-from discovery to post-marketing-present opportunities to reengineer an innovation pipeline that has fallen short. The upstream hurdles to lead identification and optimization may be eased with greater multi-sectoral collaboration, a growing array of alternatives to high-throughput screening, and the application of open source approaches. Product development partnerships and South-South innovation platforms have shown promise in bolstering the R&D efforts to tackle neglected diseases. Strategies that delink product sales from the firms' return on investment can help ensure that the twin goals of innovation and access are met. To effect these changes, both public and private sector stakeholders must show greater commitment to an R&D agenda that will address this problem, not only for industrialized countries but also globally.
authors: Sanford School of Public Policy and Duke Global Health Institute, Duke University, Durham, NC, United States. anthony.so@duke.edu
authors: A D
authors: AD
authors: So
authors: N
authors: N
authors: Gupta
authors: S K
authors: SK
authors: Brahmachari
authors: I
authors: I
authors: Chopra
authors: B
authors: B
authors: Munos
authors: C
authors: C
authors: Nathan
authors: K
authors: K
authors: Outterson
authors: J P
authors: JP
authors: Paccaud
authors: D J
authors: DJ
authors: Payne
authors: R W
authors: RW
authors: Peeling
authors: M
authors: M
authors: Spigelman
authors: J
authors: J
authors: Weigelt
mesh_terms: D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D001419:Bacteria / Q000472:pathogenicity; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D055808:Drug Discovery; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration; D024881:Drug Resistance, Bacterial; D057166:High-Throughput Screening Assays; D006801:Humans; D038622:Internationality; D007449:Investments / Q000191:economics; D058069:Neglected Diseases / Q000188:drug therapy; D058873:Pandemics / Q000517:prevention & control*; D055818:Public-Private Sector Partnerships / Q000191:economics*
chemical_list: D000900:Anti-Bacterial Agents